Download Sajiv Modi, MD Resume

11/14/2016
Sanjiv S. Modi, M.B.B.S.
Hematology & Medical Oncology
PERSONAL
Office Address:
Contact:
2614 W. Jefferson Street, Joliet, IL 60435
Tel: Office (815) 725-1355
Cell (815) 405-6860
e-mail: [email protected]
POSITIONS HELD
July 1, 1994 to June 30, 1995
Intern, Department of Medicine
University of Illinois at Chicago
Chicago, IL 60612
July 1, 1995 to June 30, 1997
Senior Resident, Department of Medicine
University of Illinois at Chicago
Chicago, IL 60612
July 1, 1997 to June 30, 2000
Fellow, Section of Hematology & Oncology
University of Illinois at Chicago
Chicago, IL 60612
July 1, 1994 to June 30, 2000
Instructor in Medicine
University of Illinois at Chicago
Chicago, IL 60612
January 2008 to December 2008
Chairman, Cancer Committee
Provena St. Joseph Medical Center, Joliet, IL
January 2011 to December 2012
Page 1|8
11/14/2016
Chairman Cancer Committee
Morris Hospital, Morris, IL
January 1, 2007 to March 30, 2012
Medical Director of Clinical Research
Joliet Oncology-Hematology Associates, LTD., Joliet, IL
January 1, 2012 to December 2013
Chair Cancer Committee
Morris Hospital, Morris, IL
March 1, 2012 to July 2014
Medical Director of Continuing Medical Education
Chairman Continuing Medical Education Committee
Presence St. Joseph Medical Center, Joliet, IL
PRESENT POSITION
July 1, 2015 to Present
Medical Director, Presence Kankakee Cancer Center, Kanakakee, IL
January 1, 2014 to Present
Member Cancer Committee
Morris Hospital, Morris, IL
November 1, 2012 to Present
BANSAN LLC -Independent reviewer - Utilization Review, Disability
review, worker's compensation review, Independent Medical Examiner,
Peer Review, Expert Witness, Medical Legal Consultant
August 1, 2000 to Present
Medical Oncologist & Hematologist,
Joliet Oncology-Hematology Associates, LTD., Joliet, IL
EDUCATION & TRAINING
1997 - 2000
FELLOWSHIP
University of Illinois at Chicago
Chicago, IL 60612
Page 2|8
11/14/2016
1995 - 1997
RESIDENCY
University of Illinois at Chicago
Chicago, IL 60612
1994 – 1995
INTERNSHIP
University of Illinois at Chicago
Chicago, IL 60612
1991-1994
Migrated to USA and took Various Licensing examination required by
ECFMG in order to qualify for Residency training in USA.
1990 – 1991
INTERNSHIP
M.S. University
Vadodara, India
1984 - 1990
M.B.B.S
Maharaja Sayajirao University
Vadodara, India
CERTIFICATES & DIPLOMAS
ABIM Board certified in Internal Medicine, 1997 & Recertified 2009
ABIM Board certified in Medical Oncology, 2001 & Recertified 2011
ABIM Board certified in Hematology, 2001& Recertified 2010
FMEGEMS I 1992
FLEX 1993
ECFMG 1993
USMLE II & III 1993
FLORIDA EXPERT WITNESS CERTIFICATE Valid Till 6/7/2017
HOSPITAL AFFILIATIONS
Presence St. Joseph Medical Center. Joliet, IL
Silver Cross Hospital. Joliet, IL
Morris Hospital. Morris, IL
LICENSURE
State of Illinois, Licensure Number 036-093810
MEMBERSHIP IN PROFESSIONAL SOCIETIES
American Society of Clinical Oncology
American Society of Hematology
Investigator Cancer Trial Support Unit
Investigator Eastern Cooperative Oncology Group
Page 3|8
11/14/2016
Forensic Expert Witness Association
HONORS
National Merit Scholarship Government of India
PUBLICATIONS
The final hours – Initiating early palliative care for advanced cancer patients
The Patient 3rd issue 2015 pages 72-73
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in
patients with locally advanced or metastatic urothelial cancer.
Cancer 2014 Apr 11;120(7):976-82. Epub 2013 Dec 11.
Walter M Stadler, David J Vaughn, Guru Sonpavde, Nicholas J Vogelzang, Scott T Tagawa,
Daniel P Petrylak, Peter Rosen, Chia-Chi Lin, John Mahoney, Sanjiv Modi, Peter Lee, Marc S
Ernstoff, Wu-Chou Su, Alexander Spira, Korinna Pilz, Richard Vinisko, Charles Schloss, Holger
Fritsch, Charles Zhao, Michael A Carducci
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of
Chicago Phase II Consortium.
Invest New Drugs 2012 Jun 7;30(3):1211-5. Epub 2011 May 7.
Manish R Sharma, Kristen Wroblewski, Blase N Polite, James A Knost, James A Wallace,
Sanjiv Modi, Bethany G Sleckman, David Taber, Everett E Vokes, Walter M Stadler, Hedy L
Kindler
Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The
University of Chicago Phase II Consortium
Sonali M. Smith, Koen van Besien, Theodore Karrison, Janet Dancey, Peter McLaughlin, Anas
Younes, Scott Smith, Patrick Stiff, Eric Lester, Sanjiv Modi, L. Austin Doyle, Everett E. Vokes,
and Barbara Pro JCO Nov 1, 2010:4740-4746; published online on September 13, 2010;
DOI:10.1200 Journal of Clinical Oncology.2010.29.2813.
Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With
Myelodysplastic Syndromes.
Roger M. Lyons, Thomas M. Cosgriff, Sanjiv S. Modi, Robert H. Gersh, John D. Hainsworth,
Allen L. Cohn, Heidi J. McIntyre, Indra J. Fernando, Jay T. Backstrom, C.L. Beach
Journal of Clinical Oncology, Vol 27, No 11 (April 10), 2009: pp. 1850-1856
Molecular Inhibition of mTOR with Temsirolimus (TORISEL , CCI-779) Is a Promising Strategy
in Relapsed NHL:
The University of Chicago Phase II Consortium. Session Type: Poster Session, Board #661-II
Sonali M. Smith, Barbara Pro, Scott Smith, Patrick Stiff, Eric Lester, Sanjiv Modi, Janet Dancey,
Everett E. Vokes, Koen van Besien
Page 4|8
11/14/2016
Azacitidine (Vidaza®) Treatment Response Assessed Using Three Alternative Dosing Schedules
in Patients with Myelodysplastic Syndromes (MDS).
Roger Lyons, MD, Thomas Cosgriff, MD, Sanjiv Modi, MD, Linda Lintz, BA*, C.L. Beach,
PharmD4,* and Jay T. Backstrom, MD, MPH4
Blood (ASH Annual Meeting Abstracts) 2005 106: Abstract 2517
All-trans-retinoic acid induces tyrosine phosphorylation of the CrkL adapter in acute
promyelocytic leukemia cells.
Yazan Alsayeda, Sanjiv Modia, Shahab Uddina, Nadim Mahmuda, Brian J. Drukerb, Eleanor N.
Fishc, Ronald Hoffmana and Leonidas C. Platanias
Experimental Hematology Volume 28, Issue 7, July 2000, Pages 826-832
Interferon-Dependent Activation of the Serine Kinase PI 3′-Kinase Requires Engagement of the
IRS Pathway but Not the Stat Pathway.
Shahab Uddin, Beata Majchrzak, Pu-Chen Wang, Sanjiv Modi, Mohammad K. Khan, Eleanor N.
Fish and Leonidas C. Platanias
Biochemical and Biophysical Research Communications Volume 270, Issue 1, 2 April 2000,
Pages 158-162
Modulation of Interleukin-6/Interleukin-6 Receptor Cytokine Loop in the Treatment of Multiple
Myeloma.
Yi-Hsiang Chen; Rei-Tsang Shiao; Jo-Mel Labayog; Sanjiv Modi; Donald Lavelle
Leukemia and Lymphoma, Volume 27, Issue 1 & 2 September 1997, pages 11 – 23
SCIENTIFIC PRESENTATIONS
June 6, 2004 - Lung Cancer for Primary Care Physicians - Saint Joseph Medical Center Grand
Rounds
August 16, 2007 Azacitidine Alternate Dose Regimens – Joliet Oncology Hematology Associates
October 18, 2010 – Polycythemia Vera - Joliet Oncology Hematology Associates
November 12, 2010 – Heparin Induced Thrombocytopenia – Provena St. Joseph Medical Center
Grand Rounds
July 25, 2012- Multiple Myeloma - Joliet Oncology Hematology Associates
August 7, 2013 – Myelodysplastic Syndrome - Joliet Oncology Hematology Associates
September 20, 2014 – Newer Oral Anticoagulants – Presence Cancer Care Annual Symposium
August 5, 2015 – Myelodysplastic Syndrome – Presence Saint Joseph Medical Center
October 10, 2015 – Personalized Medicine – Presence Cancer Care Annual Symposium
2015 – 2016 Invited Speaker Janssen Pharmaceuticals - Xarelto to treat thrombosis and reduce
thrombotic risk
Page 5|8
11/14/2016
2016 - Invited Speaker Bristol Myers Squibb – Eliquis to treat thrombosis and reduce thrombotic
risk
RESEARCH EXPERIENCE
A DUAL-COHORT, PROSPECTIVE, OBSERVATIONAL STUDY OF UNSTABLE STAGE IIIB/IV
NSCLC PATIENTS WITH AND WITHOUT BONE METASTASIS
AN OBSERVATION STUDY OF TREATMENT, OUTCOMES, AND PROGONSIS IN PATIENTS
WITH FOLLICULAR NON-HODGKIN’S LYMPHOMA
PHASE III RANDOMIZED STUDY OF XXX IN COMBINATION WITH XXX VERSES XXX AS
SECOND LINE THERAPY IN PLATINUM REFRACTORY OR RESISTANT OVARIAN CANCER
A RANDOMIZED OPEN-LABEL, CONTROLLED, CLINICAL TRIAL OF CHEMOTHERAPY
AND XXX WITH AND WITHOUT XXX IN THE FIRST-LINE TREATMENT OF SUBJECTS WITH
METASTATIC COLORECTAL CANCER
A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THREE ALTERNATIVE
DOSING REGIMENS OF SUBCUTANEOUS XXX PLUS BEST SUPPORTIVE CARE FOR THE
TREATMENT OF MYELODYSPLASTIC SYNDROMES
A RANDOMIZED, OPEN-LABEL TRIAL COMPARING TWO METHODS OF XXX BASED
THERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
AN OBSERVATIONAL COHORT STUDY OF PATIENTS WITH HER2-POSITIVE METASTATIC
BREAST CANCER
A RANDOMIZED, MULTICENTER STUDY OF COMBINATION XXX THERAPY FOLLOWED BY
SUBSEQUENT SINGLE AGENT XXX MAINTENANCE THREAPY OR BEST SUPPORTIVE CARE
IN ADVANCED NSCLC
FEASIBILITY OF A REDUCED XXX PRE- MEDICATION DOSE IN ELDERLY PATIENTS
TREATED WITH WEEKLY XXX
A NATIONAL WEB-BASED RANDOMIZED PHASE III STUDY OF XXX OR PLACEBO
FOLLOWING CONCURRENT XXX, XXX AND THORACIC RADIOTHERAPY IN PATIENTS WITH
INOPERABLE STAGE III NSCLC
A RANDOMIZED STUDY OF INTERMITTENT XXX IN COMBINATION WITH XXX AND XXX
VERSUS INTERMITTENT XXX IN COMBINATION WITH XXX AND XXX AS FIRST-LINE
TREATMENT FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
A PHASE III, MULTICENTER, PLACEBO- CONTROLLED DOUBLE-BLIND RANDOMIZEDCLINICAL TRIAL TO EVALUATE THE EFFICACY OF XXX IN COMBINATION WITH XXX
COMPARED WITH XXX ALONE FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG
CANCER AFTER FAILURE OF STANDARD FIRST-LINE CHEMOTHERAPY
A STUDY TO ASSESS THE IMPACT OF ONCE PER CYCLE CORRECTION AND MAINTENANCE
DOSING OF XXX IN SUBJECTS WITH NON-MYELOID MALIGNANCIES WITH ANEMIA DUE TO
CHEMOTHERAPY
Page 6|8
11/14/2016
A PHASE III RANDOMIZED TRIAL OF XXX BASED INDUCTION CHEMOTHERAPY IN
PATIENTS WITH N2/N3 LOCALLY ADVANCED HEAD AN NECK CANCER
A MULTICENTER, PHASE III, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING
THE EFFICACY AND SAFETY OF XXX IN COMBINATION WITH CHEMOTHERAPY IN
SUBJECTS WITH PREVIOUSLY UNTREATED METASTATIC BREAST CANCER
A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING
THE EFFICACY AND SAFETY OF XXX IN COMBINATION WITH CHEMOTHERAPY REGIMENS
IN SUBJECTS WITH PREVIOUSLY TREATED METASTATIC BREAST CANCER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, 18 WEEK PILOT
STUDY TO INVESTIGATE THE NEUROPROTECTIVE EFFECT OF XXX ON THE DEVELOPMENT
OF PERIPHERAL NEUROPATHY IN PATIENTS RECEIVING CHEMOTHERAPY FOR
ADVANCED OVARIAN CANCER
A PHASE II STUDY OF XXX ADMINISTERED INTRAVENOUSLY TO SUBJECTS WITH
METASTATIC COLORECTAL CANCER
PHASE II STUDY OF XXX ADMINISTERED INTRAVENOUSLY TO SUBJECTS WITH NSCLC
A PHASE II STUDY OF XXX ADMINISTERED INTRAVENOUSLY TO SUBJECTS WITH
RECURRENT OVARIAN CANCER
A PHASE II STUDY OF XXX ADMINISTERED INTRAVENOUSLY TO SUBJECTS WITH
METASTATIC RENAL CELL CARCINOMA
A PHASE II STUDY OF INTRAVENOUS XXX IN PATIENTS WITH LOCALLY ADVANCED OR
METASTATIC TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM
A DOUBLE – BLIND, PLACEBO CONTROLLED EVALUATION OF THE EFICACY, SAFETY AND
TOLERABILITY OF XXX IN THE TREATMENT OF BREAKTHROUGH PAIN IN CANCER
SUBJECTS
AN OPEN LABEL, LONG-TERM TREATMENT EVALUATION OF THE SAFETY OF XXX USE
FOR BREAKTHROUGH PAIN IN CANCER SUBJECTS ON CHRONIC OPIOID THERAPY
A MULTIPLE-DOSE, NON RANDOMIZED, OPEN-LABLE, MULTICENTER STUDY TO
EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF XXX IN THE TREATMENT
OF BREAKTHROUGH PAIN IN CANCER PATIENTS
XXX VS XXX WOMEN WITH CHEMOTHERAPY-NAÏVE ADVANCED NSCLC WHO ARE
PERFORMANCE STATUS 2
A RANDOMIZED DOUBLE-BLIND, MULTICENTER PHASE STUDY OF THE EFFICACY OF XXX
IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC AFTER FAILURE OF
FIRST–LINE ANTI CANCER THERAPY
A PHASE III RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF XXX AND XXX VS
XXX AND PLACEBO N PATIENTS WITH ADVANCED STAGE IIIB/IV NSCLC AFTER FAILURE
OF XXX BASED CHEMOTHERAPY
A PHASE III RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF XXX AND XXX VS
XXX IN PATIENTS WITH ADVANCED STAGE IIIB/IV NSCLC AFTER FAILURE OF XXX BASED
CHEMOTHERAPY
Page 7|8
11/14/2016
PHASE III RANDOMIZED, STUDY OF XXX VS XXX AS THIRD-LINE THERAPY IN LOCALLY
ADVANCED OR METASTATIC NSCLC
A TWO- STAGE TRIAL OF XXX IN COMBINATION WITH WEEKLY XXX FOR TREATMENT OF
PATIENTS WITH METASTATIC MELANOMA
VOLUNTEER WORK
Director JOHA Foundation (non profit arm of Joliet Oncology Hematology Associates LTD.)
Secretary for North South Foundation since 2009
President Bansan Foundation
Served on Hindu Temple of Greater Chicago Finance Committee in 2007-2008
Page 8|8